BioMarin Pharmaceutical (BMRN) statistics

Analysts' price targets and ratings, ownership, short interest, trading figures and dates for BioMarin Pharmaceutical, as the data feed reports them.

Analysts' mean target, 27 analysts
$90.19
54.1% above the price

The 27 analysts reported by the data feed have a mean price target for BioMarin Pharmaceutical of $90.19, 54.1% above the $58.51 price (range $60.00–$120.00). 7.31% of the float was sold short as of Oct 30, 2026. Institutions hold 103.1% of the shares and insiders 0.4%. Source: Yahoo Finance, read Nov 17, 2026.

Key facts

Analysts' mean target
$90.19+54.1% vs price
Analysts
27
Short interest
7.31%of float, Oct 30, 2026
Short ratio
5.73 days
Institutions
103.1%
Insiders
0.38%
Beta
0.23

Figures read . Source: Yahoo Finance (quoteSummary: key statistics, financial data, recommendation trend, major holders, insider purchases, calendar events). Analysts' targets and ratings, ownership and short interest are the data feed's figures and can lag the filings and exchange reports they come from. Figures, not advice.

Analysts' consensus as reported by the data feed

27 analysts covering BioMarin Pharmaceutical, as the data feed counts them. Price targets and ratings are other people's estimates — not facts about the company, and not advice. Distances are from the latest price the feed gave with these figures, $58.51.

Analysts' price targets for BioMarin Pharmaceutical
Mean price target$90.1954.1% above the price (+54.1%)
Median price target$89.0052.1% above the price (+52.1%)
Highest target$120.00105.1% above the price (+105.1%)
Lowest target$60.002.5% above the price (+2.5%)
Analysts with a target27

Ratings this month · 28 analysts

Strong buy 5(18%)Buy 16(57%)Hold 7(25%)
Analysts' ratings of BioMarin Pharmaceutical this month, by rating
RatingAnalystsShare
Strong buy518%
Buy1657%
Hold725%
Sell00%
Strong sell00%

The feed averages these to 1.68 on its scale of 1 (strong buy) to 5 (strong sell), which it labels “buy”.

Who owns BioMarin Pharmaceutical

Ownership of BioMarin Pharmaceutical
Held by institutions103.1%770 institutions; percent of shares outstanding
Held by institutions, of the float103.5%
Held by insiders0.38%percent of shares outstanding
Shares outstanding193.69M
Float192.75Mshares available to trade
Insiders' net purchases, six months+55.99K10 purchases (73.55K shares), 1 sales (17.56K shares)

Percentages are of shares outstanding unless the row says float. Insiders' net purchases are shares bought minus shares sold by insiders, as the data feed totals their reported trades.

Short interest as reported by the data feed

Shares sold short and not yet covered, as of Oct 30, 2026. Short interest is counted twice a month, so this is not today's figure.

Short interest in BioMarin Pharmaceutical
Shares short14.12Mas of Oct 30, 2026
Percent of float7.31%shares short ÷ float
Percent of shares outstanding7.29%shares short ÷ shares outstanding
Short ratio (days to cover)5.73shares short ÷ average daily volume

BioMarin Pharmaceutical short interest from FINRA, with its history

Trading figures

Trading figures for BioMarin Pharmaceutical
Beta0.23movement against the market; 1 moves with it
52-week high$70.98
52-week low$49.26
Average volume, 3 months2.19Mshares a day
Average volume, 10 days2.34Mshares a day

Questions and answers

What is the analysts' price target for BioMarin Pharmaceutical (BMRN)?

As reported by the data feed, the mean price target of the 27 analysts covering BioMarin Pharmaceutical is $90.19, 54.1% above the latest price of $58.51. The highest target is $120.00 and the lowest $60.00. Targets are analysts' estimates, not facts about the company and not advice.

How do analysts rate BioMarin Pharmaceutical stock?

Of the 28 ratings the data feed reports for the current month, 5 are strong buy, 16 buy, 7 hold, 0 sell and 0 strong sell.

How many BioMarin Pharmaceutical shares are sold short?

As reported by the data feed, 14.12M shares were sold short, 7.31% of the float as of Oct 30, 2026. At the average daily volume that is 5.73 days to cover. Short interest is reported twice a month; it is not today's figure.

Who owns BioMarin Pharmaceutical stock?

As reported by the data feed, institutions hold 103.1% of the shares (770 institutions) and insiders 0.4%. There are 193.69M shares outstanding, of which 192.75M are in the float.

How much does BioMarin Pharmaceutical stock move with the market?

Its beta, as reported by the data feed, is 0.23: a beta above 1 means the share has tended to move more than the market, below 1 less. Over the past 52 weeks it traded between $49.26 and $70.98.

Cite this page

Funkfolio, “BioMarin Pharmaceutical (BMRN) statistics and analyst targets”, data as of 17 November 2026. https://funkfolio.com/stock/BMRN/statistics

Underlying data: Yahoo Finance.